[Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
OBJECTIVE
To investigate the effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs.


METHODS
Eighty-five in-patients with cancer undergoing chemotherapy were randomly divided into 2 groups: Nasea group (group A, n = 43, Nasea, ramosetron hydrochloride was injected intravenously 30 minutes before chemotherapy) and ondansetron group (group B, n = 42, ondamsetron was injected intravenously 30 minutes before chemotherapy). The side effects of chemotherapy, including nausea, vomiting, anorexia, etc, were observed during the 3 days after chemotherapy.


RESULTS
The complete effective rate and effective rate of prevention of nausea, vomiting, and anorexia during the periods 0 - 6 hours, 6 - 12 hours, 24 - 48 hours, and 48 - 62 hours after chemotherapy were similar in these 2 groups. However, these rates during the period 12 approximately 24 hours after chemotherapy were significantly higher in group A than in group B (all P < 0.05). The side effects of these 2 drugs included carebarja, headache, fatigue, etc, all being mild and not significantly different between these 2 groups.


CONCLUSIONS
Effectively preventing the gastrointestinal side effects caused by chemotherapeutic drugs with an efficacy similar to that of ondansetron and seemingly lasting longer, Nasea is a promising drug.
Xie
Xiao-dong
XD
Department of Oncology, Shenyang Army General Hospital, Shenyang 110016, China.
Zheng
Zhen-dong
ZD
Liu
Da-wei
DW
Liu
Yong-ye
YY
Shan
Xue-jian
XJ
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced / Q000517:prevention & control; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D017294:Ondansetron; C071315:ramosetron